The Future State of Umbilical Cord Blood Banking
Umbilical cord blood banking or cord blood banking is the practice of preserving blood from the umbilical cord for future use. Such preserved cord blood is used in medical therapies in the similar approach as that of stem cells derived from bone marrow. Umbilical cord blood is collected from the umbilical cord of a newborn baby and also retrieved from the placenta after delivery. It is enriched with adult stem cells and these stem cells play a vital role in regulating all biological activities and in developing tissues in the human body.
To Know More About this Study Download Sample PDF
Stem cell transplantation and cord blood banking have gained a lot of popularity among the general public and medical professionals in recent times. But information about scientific aspects, its usefulness and limitations is incomplete among layers and many medical practitioners. Stem cells differ from all other types of cells in the human body, because of their ability to differentiate themselves and differentiate into specialized cells.
Key Companies Operating in this Study:
1. CBR Systems, Inc.
2. Cordlife.
3. LifeCell
4. StemCyte India Therapeutics Pvt. Ltd.
5. Vita 34
6. Americord Registry LLC.
7. ESPERITE N.V
8. Global Cord Blood Corporation.
9. SMART CELLS PLUS.
10. Cord Blood America, Inc.
Umbidical cord blood is a readily available source of hematopoietic stem cells, which are used with increasing frequency as an alternative to bone marrow or peripheral stem cells for transplantation in the treatment of malignant and non-infectious conditions in children and adults. Umbidical cord blood transplantation provides a rich source of hematopoietic stem cells, with many advantages including early availability of both human leukocyte antigen (HLA) -matched and HLA-mismatch-mismatched transmissible viral infections and Graft-versus-disease (GVHD) Reduces the risk of Stem cell transplantation, and ease of collection with little risk to the mother or newborn.
Potential limitations of umbilical cord blood disorder include insufficient stem cell doses to treat older children and adult recipients, a slower rate of growth, and the ability to transfer genetically abnormal hematopoiesia stem cells. The optimal method of umbilical cord blood flow is not yet clear, although available evidence would favor collection before placenta availability.
Umbilical cord blood can be used as a source of primitive hematopoietic stem and pluripotent progenitor cells in clinical application to reorganize the hematopoietic system and / or restore immune function in vivo. It has been used successfully as an option to develop into a new field of study in medicine for the purposes of transplantation of bone marrow or peripheral blood progenitor cells and for the treatment of diseases.